FDA accepts AstraZeneca’s NDA for breast cancer combination therapy
Pharmaceutical Technology
JUNE 13, 2023
The combination therapy is intended to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in adult patients, after recurrence or progression on or after an endocrine-based regimen.
Let's personalize your content